Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization

Journal of Vascular Surgery

Volumn 51, Issue 1, 2010, Pages 114-121

  Kadoglou, Nikolaos P E ^a,b   Sailer, Nikolaos ^a   Moumtzouoglou, Anestis ^a   Kapelouzou, Alkistis ^c   Gerasimidis, Thomas ^d   Liapis, Christos D ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; B SCAN; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLYCEMIC INDEX; GRAY SCALE ECHOGRAPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPONTIN; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; PYRROLES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 72549090857     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.07.119     Document Type: Article

References (40)

1. Ding S., Zhang M., Zhao Y., Chen W., Yao G., Zhang C., et al. The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci 336 (2008) 27-31
2. Barnett H.J., Taylor D.W., Eliasziw M., Fox A.J., Ferguson G.G., Haynes R.B., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 339 (1998) 1415-1425
3. U-King-Im J.M., Tang T., Moustafa R.R., Baron J.C., Warburton E.A., and Gillard J.H. Imaging the cellular biology of the carotid plaque. Int J Stroke 2 (2007) 85-96
4. Heliopoulos J., Vadikolias K., Mitsias P., Artemis D., Tripsianis G., Piperidou C., and Artemis N. A three-dimensional ultrasonographic quantitative analysis of non-ulcerated carotid plaque morphology in symptomatic and asymptomatic carotid stenosis. Atherosclerosis 198 (2008) 129-135
5. Nagano K., Yamagami H., Tsukamoto Y., Nagatsuka K., Yasaka M., Nagata I., et al. Quantitative evaluation of carotid plaque echogenicity by integrated backscatter analysis: correlation with symptomatic history and histologic findings. Cerebrovasc Dis 26 (2008) 578-583
6. Reiter M., Effenberger I., Sabeti S., Mlekusch W., Schlager O., Dick P., et al. Increasing carotid plaque echolucency is predictive of cardiovascular events in high-risk patients. Radiology 248 (2008) 1050-1055
7. Kadoglou N.P., Gerasimidis T., Golemati S., Kapelouzou A., Karayannacos P.E., and Liapis C.D. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 47 (2008) 55-62
8. Kadoglou N.P., Gerasimidis T., Moumtzouoglou A., Kapelouzou A., Sailer N., Fotiadis G., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 35 (2008) 661-668
9. Nakamura T., Obata J.E., Kitta Y., Takano H., Kobayashi T., Fujioka D., et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 51 (2008) 365-371
10. Yamagami H., Sakaguchi M., Furukado S., Hoshi T., Abe Y., Hougaku H., et al. Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol 34 (2008) 1353-1359
11. Cho H.J., Cho H.J., and Kim H.S. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11 (2009) 206-213
12. Kiechl S., Werner P., Knoflach M., Furtner M., Willeit J., and Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4 (2006) 801-811
13. Ren M.Y., Sui S.J., Zhang Y., Xu F.Y., Xu X.Q., Zhao J.J., et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 63 (2008) 615-622
14. Athyros V.G., Kakafika A.I., Tziomalos K., Karagiannis A., and Mikhailidis D.P. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 15 (2009) 479-489
15. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
16. Dembowski E., and Davidson M.H. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 29 (2009) 2-12
17. Liapis C.D., Bell P.R., Mikhailidis D., Sivenius J., Nicolaides A., Fernandes e Fernandes J., et al., ESVS Guidelines Collaborators. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 37 4 Suppl (2009) 1-19
18. Kadoglou N.P., Iliadis F., Angelopoulou N., Sailer N., Fotiadis G., Voliotis K., et al. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications 23 (2009) 160-166
19. Grant E.G., Benson C.B., Moneta G.L., Alexandrov A.V., Baker J.D., Bluth E.I., et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis-Society of Radiologists in Ultrasound Consensus Conference. Radiology 229 (2003) 340-346
20. Griffiths G.D., Razzaq R., Farrell A., Ashleigh R., and Charlesworth D. Variability in measurement of internal carotid artery stenosis by arch angiography and duplex ultrasonography-time for a reappraisal?. Eur J Vasc Endovasc Surg 21 (2001) 130-136
21. Rotstein A.H., Gibson R.N., and King P.M. Direct B-mode NASCET-style stenosis measurement and Doppler ultrasound as parameters for assessment of internal carotid artery stenosis. Australas Radiol 46 (2002) 52-56
22. Athyros V.G., Kakafika A.I., Tziomalos K., Papageorgiou A.A., and Karagiannis A. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol 6 (2008) 124-133
23. Tikkanen M.J., Holme I., Cater N.B., Szarek M., Faergeman O., Kastelein J.J., et al. Incremental DEcrease through Aggressive Lipid Lowering Investigators. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 103 (2009) 577-582
24. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
25. Amarenco P., Benavente O., Goldstein L.B., Callahan III A., Sillesen H., Hennerici M.G., et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 40 (2009) 1405-1409
26. Sillesen H., Amarenco P., Hennerici M.G., Callahan A., Goldstein L.B., Zivin J., et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 39 (2008) 3297-3302
27. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
28. Yu C.M., Zhang Q., Lam L., Lin H., Kong S.L., Chan W., et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93 (2007) 933-939
29. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
30. Kostapanos M.S., Milionis H.J., and Elisaf M.S. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13 (2008) 157-174
31. Leali D., Moroni E., Bussolino F., and Presta M. Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem 282 (2007) 19676-19684
32. Golledge J., McCann M., Mangan S., Lam A., and Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004) 1636-1641
33. Ohmori R., Momiyama Y., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170 (2003) 333-337
34. Tanaka N., Momiyama Y., Ohmori R., Yonemura A., Ayaori M., Ogura M., et al. Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 26 (2006) e129-e130
35. Takemoto M., Kitahara M., Yokote K., Asaumi S., Take A., Saito Y., et al. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 133 (2001) 83-88
36. Sandberg W.J., Yndestad A., Øie E., Smith C., Ueland T., Ovchinnikova O., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26 (2006) 857-863
37. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633
38. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
39. Ben-Tal Cohen E., Hohensinner P.J., Kaun C., Maurer G., Huber K., and Wojta J. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 73 (2007) 77-83
40. Nellemann B., Gormsen L.C., Dollerup J., Schmitz O., Mogensen C.E., Rasmussen L.M., et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 30 (2007) 3122-3124